The University of Brescia is an Italian public research university located in Brescia, Italy. It was founded in 1982 and is branched in 4 Faculties.The University of Brescia was officially established in 1982 with three Schools: Medicine and Surgery, Engineering, Economics and Business. However, the creation phase lasted nearly two decades, so the first attempts to open university courses in Brescia go back to the 1960s. Wikipedia.
News Article | May 4, 2017
LONDON--(BUSINESS WIRE)--LivaNova, PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, announced the presentation of data from multiple studies demonstrating the safety and the effectiveness of the PercevalTM sutureless valve for Aortic Valve Replacement (AVR) patients and the Memo 3D ReChordTM for mitral valve repair. The three data presentations on Perceval, which included a late-breaking clinical trial and a poster presentation on the Memo 3D ReChord, were unveiled at the American Association for Thoracic Surgery (AATS) Centennial meeting in Boston on April 29 – May 3, 2017. “For more than 30 years, LivaNova has been dedicated to creating and delivering safe, superior and innovative technology, like the Perceval sutureless valve and Memo 3D ReChord. We are proud to unveil these new clinical results which underscore our legacy and commitment to develop best-in-class cardiac solutions in the aortic and mitral field,” said Brian Duncan, M.D., Vice President, Medical Affairs, Cardiac Surgery at LivaNova. “Also, as we celebrate the 10th anniversary of Perceval's introduction into the AVR treatment process, we are encouraged to continue supporting cardiac surgeons to advance the standard of care and enhance the lives of patients worldwide.” Key data presented included the late-breaking clinical trial presentation, “Prospective US IDE Trial of a New Sutureless Aortic Bioprosthesis in Standard Risk Surgical Patients: One Year Hemodynamic, Clinical and Functional Outcomes,” which found that Perceval was a safe and effective AVR valve in surgical patients. The prospective, single-arm clinical trial consisting of 300 patients demonstrated that following sutureless valve therapy support, patients experienced hemodynamic relief from aortic stenosis and improvement in quality of life. At one-year follow up, health-related quality of life score increased from 63.2±22 before surgery to 85.4±18.1 at follow up. “The results of this prospective clinical trial approved under a Food and Drug Administration Investigational Device Exemption (IDE) confirmed the safety and efficacy outcomes previously reported in three European clinical trials and several independent publications both in isolated and combined procedure and in any surgical approach,” said Rakesh Suri, M.D., D.Phil., Cleveland Clinic and Cleveland Clinic Abu Dhabi. “From this prospective trial, the demonstrated hemodynamics and enhancements in patient quality of life support the practice and use of sutureless valves in patients with severe aortic valve stenosis.” “The study’s validating data provides further evidence that the use of the Perceval valve can lead to a significant reduction in cross-clamp time compared to the STS average,” said David Heimansohn, M.D., St. Vincent Heart Center, Indiana. “Since I began using the valve over three years ago, I have found that the use of Perceval is associated with a shorter procedure and recovery time, which allows patients to return back to their day-to-day lives more quickly.” The second presentation, “Sutureless Aortic Valves Versus Transcatheter Aortic Valve in Patients with Severe Aortic Stenosis and Intermediate Risk Profile: A Propensity Match Comparison in the Real World,” analyzed and compared the outcome of intermediate-risk aortic stenosis patients undergoing isolated sutureless and transcatheter aortic valve replacement (TAVR) implants. The study found that at 30-day follow up, patients treated with the sutureless valve had a significantly lower mortality rate. At mean follow up of 36 months, the overall survival and freedom from adverse events were significantly better among patients who underwent sutureless valve procedures. When compared to TAVR, the use of Perceval significantly improved patient outcomes for intermediate-risk patients with isolated aortic stenosis. “With Perceval’s technology, cardiac surgeons have a viable solution to standard bioprostheses that can decrease procedure time and reduce post-operative complications. These encouraging results demonstrated that the Perceval valve, when compared to TAVR, significantly improved patient outcomes for intermediate-risk patients with isolated aortic stenosis,” said Prof. Claudio Muneretto, M.D., University of Brescia Medical School, Italy. Adding to the growing Perceval evidence base, the data presentation, “Sutureless Aortic Valve Replacement in High Risk Patients Neutralizes Expected Worse Hospital Outcome: a Clinical Economic Analysis,” highlighted the clinical and economic impact of using the Perceval valve in high-risk patients compared to those who underwent sutured valve AVR with lower preoperative risk. The analysis found that, despite the higher patient risk profile in the Perceval group, the use of the sutureless valve resulted in no change to hospital mortality and hospital resources consumption compared to sutured valves. Finally, in addition to the Perceval sutureless valve data unveiled at AATS Week, Dr. Antonio Lio from Istituto Clinico S. Ambrogio, Milan, Italy presented a poster on a multicenter study from European and Asian centers demonstrating the benefits of the Memo 3D ReChord annuloplasty ring. As a prosthetic ring featuring an innovative chordal guiding system, the Memo 3D ReChord is used to treat patients with degenerative mitral valve disease. The study, “Early Outcomes of Mitral Valve Repair Using a New Prosthetic Ring with a Chordal Guiding System: A Multicenter Study,” showed that the use of Memo 3D ReChord during mitral valve repair procedures allowed surgeons to implant more accurately. With a short learning curve, use of the device could potentially improve surgical safety and shorten operation times for patients. To learn more about LivaNova and its portfolio of innovative cardiac solutions, please visit www.livanova.com. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively. For more information, please visit www.livanova.com.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-15-2015 | Award Amount: 6.83M | Year: 2016
CLINICAL PROBLEM AND UNMET NEED There are 11,827 patients with severe structural airway disease in Europe. Even with the current standard of care, when hospitalised this group of patients has a 22% risk of dying. Patients are currently subjected to repeated surgical interventions (stent insertion) which have a high failure rate. Other therapeutic strategies under development include synthetic tracheal scaffolds seeded with patients own stem cells. Preliminary data show that these scaffolds are poorly integrated and are susceptible to infection. TETRA PROJECT Our SME-led project will address the limitations of standard clinical care and competitor products under development and will: - Build on our successful compassionate use experience using autologous stem cell seeded scaffold-tracheal transplants in 48 patients - Follow on from our Phase I 4 patient INSPIRE clinical trial which will improve on the clinical prototype used in compassionate use cases - Conduct a 48 patient Phase II pivotal clinical trial to provide robust, quality data with validated GMP manufacturing processes to support an accelerated route to market for commercial exploitation in this orphan indication - Prepare a dossier for MAA submission BENEFITS Our product, an ATMP, aims to eliminate the need for repeated surgical interventions of high risk and limited efficacy, reduce deaths and improve the quality of life for surviving patients. If treating 20% of the patients with severe structural airway disease, we estimate that in Europe our technology will improve the quality and length of patient lives and result in savings of 517 million per year. We plan to further develop our platform technology to generate other complex tissues/organs such as bowel and liver replacements for clinical applications which will impact the lives of tens of thousands of patient in the EU with bowel and liver diseases.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2015 | Award Amount: 1.81M | Year: 2016
Women with disabilities have more difficulties to find an employment and to integrate in social day life activities than men with disabilities. This project focuses on the collective of women with disabilities from different perspectives, trying to identify needs and best practices in several EU countries, representing different cultural and socio-economic environments, for the integration and improvement of their quality of life in several respects. By applying a novel analysis method, based on the experience acquired by the exchange of researchers, innovation staff and practitioners in the European area among the participating institutions, the project will identify a set of multi-sectorial research lines, to enhance integration and involvement of this population in the society along several dimensions. The delimitation of the scope of the project to this sector of the population has several advantages. First, it is the first relevant study at a global scale that is performed in Europe on this collective. Second, it allows putting into practice and validating a novel social research method, with a strong multidisciplinary approach, with such a well delimited case study. novel potential research lines can be explored in different settings to assess their opportunity and feasibility. Fourth, it will show the impact that this collective may have on a sustainable growth in economy and society, from different respects, by empowering their capacities, so far undervalued. Fifth, it will establish a platform for cooperation among research groups and associations in EU that are aware of the situation of this collective, looking for their synergies. It is worth mentioning that advances on technologies and measures towards a stronger social engagement of disabled people have finally a positive impact also in the whole population as many examples show on how solutions have been transferred to the rest of society in fields such as computer interfaces, ergonomic solutions, etc.
Agency: European Commission | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2014 | Award Amount: 864.00K | Year: 2015
Obesity and cardio-metabolic disease represent major health problems with vast impacts on the European healthcare systems. Recent advances in tissue engineering and regenerative medicine can be used to design novel techniques aiming to boost human metabolism; thus being promising candidates for human metabolic disease treatment. However, the development of these techniques requires the creation of new technology and knowledge in chemistry, biomaterials, toxicology, physiology, molecular biology as well as business management and marketing. SMEs do not have the technical capabilities or the facilities to conduct R&D activities at the level of excellence required for such development. Academic institutions have the capacity and facilities to conduct research and design activities necessary to develop the concept into a market product. However, they do not have a viable supply chain to develop the prototype post project and to exploit the product in the market. To solve this intersectoral problem, the SCAFFY project will create an effective intersectoral co-operation between academia institutions and SMEs to advance the concept of bio-scaffold for brown adipose tissue regeneration. SCAFFY will put together knowledge, research expertise and resources from two large academic participants with business, market and commercialization experience from three SMEs to: i) ensure a high degree of collaboration between academic and industrial participants though Networking Activities, ii) go beyond the current state of the art though Researcher & Training Activities, iii) increase intersectoral transfer of knowledge though Workshop Activities, iv) ensure high level of innovation capacity though Innovation Activities, v) ensure communication to the scientific community and to the public though Dissemination and Outreach Activities.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP.2013.1.4-2 | Award Amount: 8.62M | Year: 2014
Intrinsic (or residual) stresses, resulting from manufacturing or processing steps, mostly define the performance and limit the lifetime of nanostructured materials, thin films, coatings and MEMS devices. The established techniques for micron-scale measurement of residual stress still have strong limitations, e.g. in terms of spatial resolution, lack of depth sensing, their applicability on non-crystalline materials or accessibility to industry. In this project, a European consortium is established to develop an innovative, highly reproducible and automated measurement protocol for the analysis of residual stress on a sub-micron scale, based on incremental focused ion beam (FIB) milling, along with high-resolution in situ Scanning Electron Microscopy (SEM) imaging and full field strain analysis by digital image correlation (DIC). The activities will focus on the implementation and pre-standardisation of automated FIB-SEM, DIC and inverse stress calculation procedures, under official project liaisons with both CEN and VAMAS, together with the analysis and modelling of FIB induced artefacts and stress-structure-properties relationship for the selected materials and devices. The final aim of the project will be the development of innovative design rules, implemented into simulation and optimization tools under coordination of industry partners, for the production of residual stress-controlled nanostructured materials, with specific focus on (i) multi-layered nano-coatings, (ii) micro/nano-crystalline and amorphous materials, (iii) MEMS and 3D metal interconnects. The project is expected to realize a breakthrough in measurement, standardization and modelling ability of the residual stress distribution at the sub-micron scale. The measurement techniques and the simulation tools will provide SMEs in particular with enabling technologies for the design and efficient production of innovative micro-devices with improved performance and substantially reduce development costs.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: GERI-4-2015 | Award Amount: 2.28M | Year: 2016
Increasing the participation of women in research, and promoting gender equality, is vital in strengthening the competitiveness of European research. A greater involvement of women in research will contribute not only to an increased number of skilled researchers in our institutions, but will also add a different perspective to research programmes, promote diversity, improve descion-making and contribute to enhanced creativity and innovation. This view informs the focus of this high-level consortium, who wish to work together to introduce and develop gender-sensitive organisational cultures and practices in our respective universities, thus effecting a sustainable and systemic structural change in how our institutions function. The ultimate objective of the structural change process is to work towards improved decision-making and enhanced research capacity by: incorporating gender-sensitive practices, processes and procedures in research, and; developing balanced representation of both women and men in institutional decision-making. Through the design and implementation of Gender Equality Plans, SAGE partner institutions will uncover, assess, and address the barriers to equal participation of women and men in research and decision making. SAGE is designed using the concepts and methodology of structural change to deliver a more equitable research landscape. The composition of the consortium will allow for transfer of learning, thus increasing the efficacy of Gender Equality Plans and their capacity to deliver greater gender balance and gender awareness in research and decision making.
Latronico N.,University of Brescia |
Bolton C.F.,Queen's University
The Lancet Neurology | Year: 2011
Critical illness polyneuropathy (CIP) and myopathy (CIM) are complications of critical illness that present with muscle weakness and failure to wean from the ventilator. In addition to prolonging mechanical ventilation and hospitalisation, CIP and CIM increase hospital mortality in patients who are critically ill and cause chronic disability in survivors of critical illness. Structural changes associated with CIP and CIM include axonal nerve degeneration, muscle myosin loss, and muscle necrosis. Functional changes can cause electrical inexcitability of nerves and muscles with reversible muscle weakness. Microvascular changes and cytopathic hypoxia might disrupt energy supply and use. An acquired sodium channelopathy causing reduced muscle membrane and nerve excitability is a possible unifying mechanism underlying CIP and CIM. The diagnosis of CIP, CIM, or combined CIP and CIM relies on clinical, electrophysiological, and muscle biopsy investigations. Control of hyperglycaemia might reduce the severity of these complications of critical illness, and early rehabilitation in the intensive care unit might improve the functional recovery and independence of patients. © 2011 Elsevier Ltd.
Wabnitz S.,University of Brescia
Optics Letters | Year: 2014
We analyze the nonlinear stage of modulation instability in passively mode-locked fiber lasers leading to chaotic or noise-like emission. We present the phase-transition diagram among different regimes of chaotic emission in terms of the key cavity parameters: amplitude or phase turbulence, and spatio-temporal intermittency. © 2014 Optical Society of America.
Alessandri I.,University of Brescia
Journal of the American Chemical Society | Year: 2013
A remarkable enhancement of Raman scattering is achieved by TiO2 shell-based spherical resonators in the absence of plasmonic enhancers. This effect is ascribed to the synergistic combination of high refractive index of the shell layer, multiple light scattering through the spheres, and related geometrical factors and can be exploited to fabricate a new generation of self-diagnostic, recyclable SERS-active substrates. © 2013 American Chemical Society.
Agency: European Commission | Branch: H2020 | Program: MSCA-IF-EF-ST | Phase: MSCA-IF-2015-EF | Award Amount: 168.28K | Year: 2016
The lack of objective and robust measurements of motor recovery is a general problem in stroke rehabilitation. After the ischemic event, the motor impairment is assessed using clinical scales that provide only a general overview of the patients conditions, without detailed information on the activation of the individual muscles and the pathological co-contractions. In recent years, the hypothesis that the coordination of multiple muscles is wired at the neural level in a synergistic way has received strong experimental evidence. Therefore, the possibility to better understand the recruitment of multiple muscles and use this information for the assessment of motor recovery is extremely relevant for stroke rehabilitation. The project NeuralCon aims to investigate the neural mechanisms behind the control of multiple muscles of the lower limb in healthy individuals and its degeneration in acute stroke patients. The project will address the characterization of the neural coupling between muscles using innovative signal processing approaches applied to the high-density surface electromiographic signals during voluntary contractions. From the electromiographic signals, we will extract information regarding the coupling between multiple motor neurons in different motor pools. The final aim will be the development of a new generation of biomarkers based on the concurrent neural activation of several muscles in the lower limb of acute stroke individuals. The project will combine expertise in several fields: neuroscience of human movement, clinical neurophysiology, stochastic signal processing and computational neuroscience. The NeuralCon project will produce substantial progress toward a better understanding of the neural pathways involved in the coordination of voluntary movements and its modifications in cerebrovascular diseases.